JP2017502023A - 眼疾患を治療する組成物および方法 - Google Patents

眼疾患を治療する組成物および方法 Download PDF

Info

Publication number
JP2017502023A
JP2017502023A JP2016540993A JP2016540993A JP2017502023A JP 2017502023 A JP2017502023 A JP 2017502023A JP 2016540993 A JP2016540993 A JP 2016540993A JP 2016540993 A JP2016540993 A JP 2016540993A JP 2017502023 A JP2017502023 A JP 2017502023A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
subject
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016540993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502023A5 (enExample
Inventor
バンサル，レーカー
Original Assignee
ノーベルメッド セラピューティクス インコーポレイテッド．
ノーベルメッド セラピューティクス インコーポレイテッド．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノーベルメッド セラピューティクス インコーポレイテッド．, ノーベルメッド セラピューティクス インコーポレイテッド． filed Critical ノーベルメッド セラピューティクス インコーポレイテッド．
Publication of JP2017502023A publication Critical patent/JP2017502023A/ja
Publication of JP2017502023A5 publication Critical patent/JP2017502023A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2016540993A 2013-12-24 2014-08-06 眼疾患を治療する組成物および方法 Pending JP2017502023A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920541P 2013-12-24 2013-12-24
US61/920,541 2013-12-24
PCT/US2014/049938 WO2015099838A2 (en) 2013-12-24 2014-08-06 Compositions and methods of treating ocular diseases

Publications (2)

Publication Number Publication Date
JP2017502023A true JP2017502023A (ja) 2017-01-19
JP2017502023A5 JP2017502023A5 (enExample) 2017-09-14

Family

ID=53479755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540993A Pending JP2017502023A (ja) 2013-12-24 2014-08-06 眼疾患を治療する組成物および方法

Country Status (6)

Country Link
US (2) US10183989B2 (enExample)
EP (1) EP3086809A4 (enExample)
JP (1) JP2017502023A (enExample)
AU (1) AU2014370404A1 (enExample)
CA (1) CA2934462A1 (enExample)
WO (1) WO2015099838A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
IL261188B (en) 2016-03-04 2022-08-01 Jn Biosciences Llc An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
WO2019033081A1 (en) * 2017-08-11 2019-02-14 Massachusetts Eye And Ear Infirmary INHIBITION OF THE SUPPLEMENTARY ALTERNA PATHWAY FOR THE TREATMENT OF RETINAL ISCHEMIC LESION AND GLAUCOMA
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
BR112020019907A2 (pt) 2018-04-03 2021-01-05 Ngm Biopharmaceuticals, Inc. Agentes de ligação a c3 e métodos de uso dos mesmos
EP3586865A1 (en) * 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
CN109999015A (zh) * 2019-04-24 2019-07-12 江苏省中医药研究院 紫草素在制备预防或治疗房颤药物中的用途
CR20220611A (es) 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
IL301762A (en) * 2020-10-07 2023-05-01 Line 6 Biotechnology Inc Methods and materials for the treatment of eye diseases
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015139A1 (en) * 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
JP2012525829A (ja) * 2009-05-06 2012-10-25 ノバルティス アーゲー 補体タンパク質Ｃ３ｂを標的とする抗体の組成物および方法
US20130039925A1 (en) * 2007-03-23 2013-02-14 Rekha Bansal Alternative pathway specific antibodies for treating arthritis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171320A1 (en) * 2001-11-09 2003-09-11 Guyer David R. Methods for treating ocular neovascular diseases
DK1931379T3 (da) * 2005-10-07 2013-08-19 Sec Dep For Health Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme
ES2551202T5 (es) 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
HUE026496T2 (en) 2006-03-08 2016-06-28 Archemix Llc Complement-binding aptamers and anti-C5 agents for treating eye diseases
WO2011112850A2 (en) 2010-03-10 2011-09-15 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
AU2008262048B2 (en) * 2007-06-07 2013-09-26 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
US20190202898A9 (en) * 2012-04-03 2019-07-04 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
EP2834271B1 (en) 2012-04-03 2019-01-16 NovelMed Therapeutics, Inc. Humanized and chimeric anti-factor bb antibodies and uses thereof
CN104220453B (zh) * 2012-04-03 2018-03-09 诺沃姆德治疗公司 人源化的嵌合抗因子c3抗体及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130039925A1 (en) * 2007-03-23 2013-02-14 Rekha Bansal Alternative pathway specific antibodies for treating arthritis
US20100015139A1 (en) * 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
JP2012525829A (ja) * 2009-05-06 2012-10-25 ノバルティス アーゲー 補体タンパク質Ｃ３ｂを標的とする抗体の組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ＪＯＵＲＮＡＬ ＯＦ ＢＩＯＬＯＧＩＣＡＬ ＣＨＥＭＩＳＴＲＹ, vol. 284, no. 16, JPN6018014226, 2009, pages 10473 - 10479, ISSN: 0003934449 *

Also Published As

Publication number Publication date
AU2014370404A1 (en) 2016-07-07
US20190169279A1 (en) 2019-06-06
US10183989B2 (en) 2019-01-22
WO2015099838A3 (en) 2015-10-29
EP3086809A4 (en) 2017-11-29
US20160319002A1 (en) 2016-11-03
US10696740B2 (en) 2020-06-30
EP3086809A2 (en) 2016-11-02
WO2015099838A2 (en) 2015-07-02
CA2934462A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
JP2017502023A (ja) 眼疾患を治療する組成物および方法
JP2021046431A (ja) 血管性眼疾患を処置するための方法および製剤
JP6836512B2 (ja) 組織透過性ペプチドと抗血管内皮細胞成長因子製剤が融合された融合タンパク質を有効成分として含む眼疾患の予防及び治療用薬学的組成物
JP7107914B2 (ja) ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体
MX2014004449A (es) Tratamiento de enfermedad ocular.
TWI881273B (zh) 眼科疾病之個人化治療
JP2010528047A5 (enExample)
TW202535932A (zh) 眼科疾病之治療
US20100015139A1 (en) METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
JP2015532303A (ja) 溶血性疾患を治療するための補体第２経路特異的抗体
AU2011224224B2 (en) Humanized and chimeric anti-properdin antibodies
KR20200138290A (ko) C3-결합제 및 이의 사용 방법
JP2018530574A (ja) 患者の加齢黄斑変性を治療する方法
CN113166237A (zh) 抗fam19a5抗体的用途
EP2536433B1 (en) Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases
CN114450068A (zh) 用于治疗急性神经炎性损伤的方法和剂
JP7560185B2 (ja) 補体経路阻害剤及び血管新生阻害剤を含む融合タンパク質並びにその使用
JP2020518641A5 (enExample)
JP2023545579A (ja) 眼疾患の治療のための方法と薬剤
CN114423788B (zh) 抗nrp1a抗体及其用于治疗眼或眼部疾病的用途
RU2802307C2 (ru) C3-связывающие агенты и способы их применения
EA049293B1 (ru) АНТИ-Nrp1A АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ГЛАЗ ИЛИ ГЛАЗНЫХ ЗАБОЛЕВАНИЙ
JP2025501913A (ja) 血管新生阻害剤結合抗Ｃ３ｂ抗体又は抗Ｃ５抗体及びその使用
CN118076637A (zh) 缺氧诱导因子-1α抑制剂
RU2019132064A (ru) Оптимизированные композиции антител для лечения заболеваний глаз

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180925

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181211